An interventional study of Comprehensive Pre-ESRD Patient Education (CPE) and Provision of the freely available resources for Kidney Disease Education in Chronic Kidney Disease, End Stage Renal Disease and Hemodialysis, sponsored by VA Office of Research and Development. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 51st largest by enrollment of the 638 interventional ones that give a count, is one of 35 that started in 2020, is one of 287 with no phase, reaches primary completion later than 19 of the 95 other live ones, and was the 559th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
Basilea Pharmaceutica · Sites in United States
Ages 18–80 · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 35 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 656 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 611 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
VA Office of Research and Development has 8 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is intended to correct an important systemic deficit in the care of chronic kidney disease (CKD), VHA's fourth most common healthcare condition with high mortality and healthcare burden. Currently, many Veterans with CKD have poor awareness of their condition. This leads to suboptimal care. The investigators anticipate that the proposed comprehensive pre-end stage renal disease (ESRD) education (CPE) will enhance Veterans' CKD knowledge and their confidence in making an informed selection of an appropriate dialysis modality, and lead to an increase in the use of home dialysis (HoD) - an evidence-based, yet underutilized dialysis modality. Further, this study will allow us to examine whether such Veteran-informed dialysis choice can improve Veteran and health services outcomes. If successful, this study may deliver a ready to roll-out strategy to meet the CKD care needs of the Veterans and reduce VHA healthcare costs.
Chronic kidney disease (CKD) is the 4th most common diagnosis among Veterans. Each year, over 13,000 Veterans transition from CKD to end stage renal disease (ESRD), a disease with high mortality and poor health related quality of life (HRQoL). Over 52,000 Veterans with ESRD are currently on dialysis and CKD/ESRD care costs VA over $18 billion per year. The majority of Veterans progressing from CKD to ESRD have limited to no awareness of CKD and its treatment options. This hinders Veterans' informed dialysis selection resulting in a gross underuse (7%) of home dialysis (HoD). As there are no significant differences in mortality among different dialysis modalities, VHA National Kidney Program and professional renal societies advocate informed dialysis selection and greater use of HoD to facilitate improvements in Veterans' post-ESRD clinical and health services utilization outcomes.
Reports from Europe and Canada show that providing comprehensive pre-ESRD patient education (CPE) improves the quality of CKD care and empowers patients to make informed dialysis modality selection. Data further show that informed modality selection substantially corrects the underuse of HoD as desired by the healthcare systems, including VHA.
However, across VHA, many Veterans with CKD are identified too late to benefit from CPE; and even for those identified and under renal care, the availability of CPE is limited. This results in suboptimal pre-ESRD care and preparation, and continued low HoD utilization. Thus, there is an urgent systemic need to provide CPE to all pre-ESRD (stage 4 and 5 CKD) Veterans and study its effectiveness prospectively within the VHA.
This study aims to evaluate the impact of the comprehensive pre-ESRD patient education on high-impact outcomes for Veterans and health services, across a local Veterans Healthcare System (VHS). The investigators will compare the impact of CPE (intervention), delivered either in-person or through telemedicine, with the usual care (control) enhanced by the provision of the self-learning CKD information among Veterans with advanced CKD across the North Florida/South Georgia VHS.
The investigators' study has four aims, consisting of one primary outcome (HoD use) and multiple secondary outcomes, to help us understand the impact of CPE on patients' informed decision making and on important post-ESRD clinical, patient-reported, and health services outcomes.
Aim 1: Compare the impact of CPE on Veterans' knowledge of CKD, their confidence in dialysis decision making, and their selection of dialysis modality, between the CPE and usual care groups.
H1.1: CPE will improve Veterans' knowledge of CKD and its management. H1.2: CPE will improve Veterans' confidence in making an informed selection of a dialysis modality.
H1.3: CPE will increase Veterans' selection of HoD. Aim 2: Compare Veterans' actual use of HoD (Primary Outcome) between the CPE and usual care groups.
H2.1: Veterans in the CPE group will show increased HoD use. Aim 3: Examine Veterans' perceived satisfaction with CPE, explore their preferences for F2F- or Tele-CPE, and investigate barriers and facilitators in the selection and use of their preferred dialysis modality. (Qualitative) Aim 4: Compare the following post-ESRD secondary outcomes between the CPE and usual care groups.
Patient reported outcomes: 1) health-related quality of life and 2) satisfaction with dialysis; clinical outcomes: 3) time to ESRD, 4) estimated glomerular filtration rate at ESRD, 5) need for inpatient initiation of dialysis, and 6) vascular access status at ESRD; and health services utilization outcomes: 7) number of inpatient stays, and 8) number of outpatient visits, from enrollment to 90-day post ESRD period.
H4: Veterans in the CPE group will show improvement in these secondary outcomes.
Findings from this study will help to achieve the long-term goal of better meeting the needs of Veterans with advanced CKD by improving Veterans' knowledge of CKD and its management, and promoting evidence-based Veteran-centered ESRD care.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
This study's enrollment of 656 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
These patients will receive CPE for a total of up to 3 session in an intent-to-teach format, either via Face-to-face or telemedicine delivery.
Other: Comprehensive Pre-ESRD Patient Education (CPE)
This group will receive usual care. This care will be enhanced by providing them with the freely available education material for the Kidney Disease Education
Other: Provision of the freely available resources for Kidney Disease Education
Structured education session/s
Also known as: Kidney Disease Education, CKD education, dialysis education
freely available resources
Also known as: information brochure
Home Dialysis Use
Patient receiving either CPE or Enhanced usual care (EUC) will be followed for the diagnosis of ESRD and initiation of dialysis. The investigators will follow the use of peritoneal dialysis or home hemodialysis at day 90 into the dialysis as the home dialysis (HoD) use primary outcome.
Time frame: 0-48 months
Home Dialysis selection
post-CPE/EUC dialysis modality selection and examining the rates of home dialysis selection. post-CPE assessments will be made when subject is deemed confident in dialysis selection (see selection outcome). Post-EUC assessments will be made 10 days after the provision of the education material.
Time frame: 0-4 weeks
Kidney Disease Knowledge
pre- and post- kidney disease knowledge assessments after CPE/EUC. post-CPE assessments will be made when subject is deemed confident in dialysis selection (see selection outcome). Post-EUC assessments will be made 10 days after the provision of the education material.
Time frame: 0-4 weeks
confidence in dialysis decision making
post-CPE/EUC confidence in dialysis decision making. ). Intent-to-Teach will be assessed by confidence for dialysis decision making (defined by confidence rating of "quite confident" or "very confident"); those with suboptimal scores ("not at all confident" or "a little confident") or "uncertain of the dialysis modality choice," will undergo repeat CPE sessions weekly for up to 3 sessions. Based on our pilot studies showing the need for about 1.7 CPE session, the investigators expect that patients enrolled in CPE group will do post-CPE Aim 1 data collection (secondary outcome) at an average of 10 days
Time frame: 0-4 weeks
post-ESRD Kidney Disease Quality of life-36
post CPE/EUC. This will only be measured in subjects that start dialysis therapy, 90 days post initiation of dialysis.
Time frame: 3-48 months
Satisfaction on Dialysis
post CPE/EUC. This will only be measured in subjects that start dialysis therapy, 90 days post initiation of dialysis.
Time frame: 3-48 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Mar 2020 (actual). Primary completion is estimated for Dec 2026, 81 months after the start.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 81 months is above that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →